Gemcitabine and nonplatinum combinations in non-small-cell lung cancer

ONCOLOGY

Volumn 15, Issue 3 SUPPL. 6, 2001, Pages 18-25

  Natale, Ronald B ^a  

^a Salick Health Care Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; PLATINUM DERIVATIVE;

HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; REVIEW; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; HUMAN; LUNG NEOPLASMS; PLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 0035292571     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994.
2. Anderson H, Lund B, Bach F, et al: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994.
3. Gatzemeier U, Shepherd FA, LeChevalier T, et al: Activity of gemcitabine in patients with non-small-cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 32A:243-248, 1996.
4. Fukuoka M, Takada M, Yokoyama A, et al: Phase II studies of gemcitabine for non-small-cell lung cancer in Japan. Seminars in Oncol 24(suppl 7):42-46, 1997.
5. Yokoyama A, Nakai Y, Yoneda S, et al: Activity of gemcitabine in the treatment of patients with non-small-cell lung cancer: A multicenter phase II study. Anti-Cancer Drugs 8:574-581, 1997.
6. Anderson H, Hopwood P, Stephens RJ, et al: Gemcitabine plus best supportive care vs best supportive care in inoperable non-small-cell lung cancer: A randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 83:447-453, 2000.